EDITORIAL
Published on 16 Jun 2022
Editorial: Differential Efficacy of Immune Checkpoint Inhibitors due to Age and Sex Factors
doi 10.3389/fimmu.2022.941254
- 1,454 views
- 2 citations
- Frontiers in Immunology
- Cytokines and Soluble Mediators in Immunity
- Research Topics
- Differential Efficacy of Immune Checkpoint Inhibitors due to Age and Sex Factors
Differential Efficacy of Immune Checkpoint Inhibitors due to Age and Sex Factors
14k
Total Downloads
36k
Total Views and Downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
ORIGINAL RESEARCH
Published on 14 Feb 2022
Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer
doi 10.3389/fimmu.2022.807575
- 2,472 views
- 11 citations
ORIGINAL RESEARCH
Published on 10 Dec 2021
Clinical and Prognostic Significance of Tumor-Infiltrating CD8+ T Cells and PD-L1 Expression in Primary Gastrointestinal Stromal Tumors
doi 10.3389/fonc.2021.789915
- 2,234 views
- 13 citations
REVIEW
Published on 16 Nov 2021
Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
doi 10.3389/fimmu.2021.786046
- 3,672 views
- 31 citations
ORIGINAL RESEARCH
Published on 05 Nov 2021
Single-Cell RNA Sequencing Reveals the Heterogeneity of Tumor-Associated Macrophage in Non-Small Cell Lung Cancer and Differences Between Sexes
doi 10.3389/fimmu.2021.756722
- 19,134 views
- 62 citations
Published in
Frontiers in Immunology
- Cytokines and Soluble Mediators in Immunity
- Viral Immunology
- Cancer Immunity and Immunotherapy
Participating Journals
Frontiers in Oncology
- 3.5 impact factor
- 6.2 citescore
Impact
- 36kTopic views
- 21kArticle views
- 14kArticle downloads